Product Description
CAR-T cells for Relapsed/Refractory Multiple Myeloma (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT05270928)
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: CAR-T
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chunrui Li
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CIBI346Y002 | P1 |
Unknown status |
Multiple Myeloma |
2024-02-28 |
|
| CIBI346Y001 | P1 |
Completed |
Multiple Myeloma |
2022-12-21 |